

PRELIMINARY RESEARCH

Open Access

Preliminary clinical assessment of the relationship between tumor $\alpha v \beta 3$ integrin and perfusion in patients studied with [^{18}F]fluciclatide kinetics and [^{15}O]H $_2$ O PET

Laura M Kenny^{1,2*}, Giampaolo Tomasi¹, Federico Turkheimer³, James Larkin⁴, Martin Gore⁴, Cathryn S Brock², Stephen Mangar² and Eric O Aboagye¹

Abstract

Background: [^{18}F]fluciclatide, a peptide ligand with high affinity for $\alpha v \beta 3/\alpha v \beta 5$ integrins, is a proposed biomarker of tumor angiogenesis. The study rationale was to perform a preliminary evaluation of the relationship between tumor [^{18}F]fluciclatide uptake and perfusion by [^{15}O]H $_2$ O PET.

Methods: Patients with non-small cell lung cancer and melanoma underwent dynamic imaging with arterial sampling following injection of [^{15}O]H $_2$ O and [^{18}F]fluciclatide. Quantification was performed using a one-tissue compartmental model for [^{15}O]H $_2$ O and a two-tissue model for [^{18}F]fluciclatide at volume-of-interest level, and SUV at voxel level.

Results: Tumor binding potential (k_3/k_4 ratio) of [^{18}F]fluciclatide tumor was 5.39 ± 1.46 , consistent with previous studies in breast cancer metastases. Voxel-by-voxel maps of [^{18}F]fluciclatide delivery strongly correlated with [^{15}O]H $_2$ O-based perfusion ($p < 10^{-4}$ tumor, $1,794 \pm 1,331$ voxels). Interestingly, this correlation was lost when retention of [^{18}F]fluciclatide at late time-points was compared with perfusion ($p > 0.15$).

Conclusions: Our study suggests tumor [^{18}F]fluciclatide retention is unrelated to tumor perfusion, supporting use of late (60-min) imaging protocols in patients.

Keywords: Fluciclatide; Perfusion; Angiogenesis; PET; Cancer

Background

Tumor angiogenesis is essential for cancer survival [1]. Many novel therapeutics have been developed which aim to target this process by acting as either angiogenesis inhibitors (e.g. by blocking the action of vascular endothelial growth factor) or as vascular disrupting agents, which target the extracellular matrix [2,3]. Despite the recent advances in therapeutics, there remains a paucity of effective biomarkers which can predict the response of tumors *in vivo* to these treatments. One area of promise is the development of imaging agents that target the $\alpha v \beta 3$ and $\alpha v \beta 5$ integrins - a set of transmembrane proteins

essential for maintaining the relationship between the cell and the extracellular matrix and that have been found to be upregulated on tumor vascular neoendothelium [4,5].

[^{18}F]fluciclatide is an arginine-glycine-aspartic acid (RGD) peptide which binds the $\alpha v \beta 3$ and $\alpha v \beta 5$ integrins with high affinity [6]. We have previously studied the dosimetry and biodistribution of this compound labelled with F-18 in healthy volunteers with positron emission tomography (PET) [7] and the uptake profile of the tracer in patients with metastatic breast cancer [8]. The latter study showed significantly higher radio-tracer uptake in lung metastases from breast cancer compared to normal lung tissue. [^{18}F]galacto-RGD is a similar promising agent for studying integrin-related angiogenesis developed by Wester's group [9], and subsequently studied by Beer et al. who demonstrated that there is high uptake of this compound in a variety of

* Correspondence: l.kenny@imperial.ac.uk

¹Department of Surgery and Cancer, Hammersmith Campus, Imperial College London, London, UK

²Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK

Full list of author information is available at the end of the article

cancers including melanoma [10] and that uptake correlates with expression of the $\alpha\beta3$ integrin measured using immunohistochemistry [11].

The purpose of this study was to understand the relationship between perfusion assessed by $[^{15}\text{O}]\text{H}_2\text{O}$ and ^{18}F -fluciclatide kinetics in non-small cell lung cancer (NSCLC) and melanoma, where Phase 1 trials of humanized antibodies and peptides targeted to integrins have shown promise [12,13]. These two tumor types have also been shown to have varying degrees of $\alpha\beta3$ and $\alpha\beta5$ expression on tumor cells relative to vascular endothelium with melanoma suggested to have expression on both tumor and vascular endothelium and NSCLC suggested to have expression predominantly on the vascular endothelium [4]. The underlying hypothesis for the study was that fluciclatide retention in tumors is initially dependent on perfusion, but at later timepoints, retention is independent of perfusion.

Methods

Patients were recruited from oncology clinics at the Imperial College NHS Healthcare trust and the Royal Marsden Hospital NHS Trust. The study was approved by the hospital Local Research Ethics Committee in accordance with the Helsinki Declaration revised guidelines (2008). The eligibility criteria were as follows: patients aged ≤ 80 years old with a histological proven NSCLC or melanoma, and one site of measureable disease of ≥ 2 -cm diameter, with a treatment-free interval of 3 weeks (or 4 weeks for radiotherapy to the imaging site), life expectancy of at least 3 months, haemoglobin ≤ 10 g/dL, granulocyte count of $\geq 1.5 \times 10^9$, platelet count of $\geq 100 \times 10^9$, adequate hepatic function; exclusion criteria: pregnant or lactating patients, sexually active patients who are not employing adequate contraception. Additional details are provided in Table 1.

Radiosynthesis of ^{18}F -fluciclatide and PET scanning procedure

The chemical synthesis of the precursor of fluciclatide has previously been described [6], radiolabelling was performed at Hammersmith Imanet as previously described on an

automated module (TRACERlab FX $_{\text{F-N}}$; GE Healthcare). The specific activity and radiochemical purity of the injectate, determined by high-performance liquid chromatography (HPLC), was 320 GBq/ μmol and 99.7 %, respectively.

All patients were scanned on a PET-CT (GE-Discovery RX) scanner after being positioned such that the field of view (FOV) included the tumor volume of interest. The axial FOV of the scanner was 15.7 cm and the transaxial FOV was 70 cm. A low-dose CT scan (20 mA and 120 kV) was used for attenuation correction prior to the PET scan. A target dose of 600 MBq $[^{15}\text{O}]\text{H}_2\text{O}$ was injected i.v. over 20 s followed by a 30-s flush with normal saline. Dynamic PET scanning was done for 8 min and 40 s with the following frame durations: 30 s \times 1, 20 s \times 1, 5 s \times 22, 10 s \times 3, 30 s \times 5, and 60 s \times 3. After a 2-min break to allow for radioactive decay (^{15}O half-life = 2.04 min), the $[^{18}\text{F}]\text{fluciclatide}$ scan was performed. $[^{18}\text{F}]\text{fluciclatide}$ was administered by a bolus i.v. injection over 10 to 30 s. The PET acquisition was conducted as a single bed position dynamic scan (three-dimensional acquisition) centred on the tumor volume of interest (VOI) for 66.5 min. Data were binned into the following time frames: 10 s \times 10, 20 s \times 4, 30 s \times 4, 60 s \times 7, 120 s \times 4, 300 s \times 3, and 600 s \times 3. Sinograms were Fourier-rebinned into two-dimensional slices and reconstructed (with correction for attenuation, scatter, and dead time) using filtered back-projection (ramp filter kernel full-width-at-half-maximum of 2.0 mm). The final images had $128 \times 128 \times 47$ voxels of $2.62 \times 2.62 \times 2.42$ mm³.

In order to derive an input function, blood samples were taken during the $[^{15}\text{O}]\text{H}_2\text{O}$ scan *via* a radial artery cannula continuously at a rate of 5 mL/min for the first 9 min 40 s; discrete samples were taken at 3, 6, and 8 min 40 s. Similarly, continuous arterial sampling (5 mL/min) was performed for 10 min during the $[^{18}\text{F}]\text{fluciclatide}$ scan; seven discrete samples (5 to 10 mL) were taken at 2.5, 5, 10, 15, 30, 45, 60 min. Metabolite analyses were performed on the 2.5-, 5-, 10-, 30-, and 60-min samples. The computation of $[^{18}\text{F}]\text{fluciclatide}$ parent fraction and input function was carried out as described in [7].

Data analysis

Volumes-of-interest (VOIs) were manually defined around visible tumors from the $[^{18}\text{F}]\text{fluciclatide}$ summed images using the Analyze software (Version 7). The same VOIs were applied to the $[^{15}\text{O}]\text{H}_2\text{O}$ scan to extract tumor time-activity curves (TACs) for both tracers.

To estimate the perfusion from the $[^{15}\text{O}]\text{H}_2\text{O}$ data, a one-tissue compartment model was employed:

$$C_T(t) = (1 - V_b) \times [K_1 \times [C_a(t) \otimes \exp(-k_2 \times t)] + V_b C_a(t)] \quad (1)$$

In Equation 1, $C_T(t)$ indicates the tumor TAC, $C_a(t)$ the measured radioactivity concentration in arterial

Table 1 Demographics of the patients studied

Patient	Age	Diagnosis	Stage	Dynamic imaging region
1	81	Melanoma	IV	Thorax
2	62	NSCLC*	IIIA	Thorax
3	57	NSCLC	IIIB	Thorax/Neck
4	59	NSCLC	IB	Thorax
5	66	NSCLC	IV	Thorax
6	79	Melanoma	IV	Knee
7	59	NSCLC	IV	Thorax

NSCLC, non-small cell lung cancer.

blood, K_1 the regional blood flow (mL/cm³/min), k_2 (1/min) the transfer rate from tissue to blood, V_b (unitless) the blood volume fraction and \otimes the convolution operator. K_1 , k_2 , and V_b were estimated for each VOI by fitting $C_T(t)$ to Equation 1 using the standard weighted non-linear least squares (WNLLS). WNLLS minimizes the weighted residual sum of squares (WRSS)

$$WRSS(p) = \sum_{i=1}^n w_i \left[C(t_i, p)^{MODEL} - C_T(t_i) \right]^2 \quad (2)$$

with p , t_i , and n indicating respectively the parameter vector $[K_1; k_2; V_b]$, the mid-time of the i th frame, and the number of frames. In Equation 2 weights w_i were set to

$$w_i = \frac{\Delta_i}{C(t_i) \exp(\lambda t_i)} \quad (3)$$

Tomasi G 2009, [14] with Δ_i and λ indicating respectively the duration of the i th frame and the half-life of ¹⁵O. The delay between $C_a(t)$ and $C_T(t)$ was modelled by shifting $C_T(t)$ of i seconds ($i = 0, 1, \dots, 30$) and then retaining the value of the delay which gave rise to the smallest WRSS.

A two-tissue reversible compartment model was used to model [¹⁸F]fluciclatide kinetics, consistent with our previous study [8]. The metabolite-corrected measured arterial concentration of [¹⁸F]fluciclatide was used as input function for estimating with WNNLS the parameters K_1 (mL/cm³/min), k_2 (1/min), k_3 (1/min), k_4 (1/min), V_b (unitless) for each VOI. Weights were computed from Equation 3. The parameter k_3/k_4 ratio - a measure of the binding potential - was then computed for each VOI; as we previously reported [8], this parameter was the best of a number of parameters examined to differentiate between healthy and tumor VOIs.

K_1 , k_2 , and V_b were also estimated at the voxel level for [¹⁵O]H₂O using the standard Basis Function Method approach [15]. The final maps, however, were extremely noisy because of the high noise of [¹⁵O]H₂O data and we did not include them in the analysis. Parametric maps were not generated in the case of [¹⁸F]fluciclatide because of the difficulty of fitting a five-parameter model at the voxel level. To analyze the correlation between perfusion and [¹⁸F]fluciclatide uptake at the voxel level we employed the following semi-quantitative parameters. For [¹⁵O]H₂O we used

$$SUV_{water} [m^2/L] = \frac{\text{mean}[C_T(t)_{0-1.5 \text{ min}}]}{\frac{\text{Injected dose}}{BSA}} \quad (4)$$

In Equation 4, we arbitrarily chose 1.5 min as the final time, instead of the scan duration of 8 min, to define a parameter describing [¹⁵O]H₂O delivery (i.e. flow) before

washout took place. To measure [¹⁸F]fluciclatide retention, we employed

$$SUV_{fluci \text{ RETENTION}} [m^2/L] = \frac{C_T(t_i)}{\frac{\text{Injected dose}}{BSA}} \quad (5)$$

In Equations 4 and 5, BSA denotes the body surface area, and t_i in Equation 5 indicates the mid-time of the last frame of the [¹⁸F]fluciclatide scan (60.5 min). We also defined a parameter describing [¹⁸F]fluciclatide delivery as

$$SUV_{fluci \text{ DELIVERY}} [m^2/L] = \frac{\text{mean}[C_T(t)_{0-1.5 \text{ min}}]}{\frac{\text{Injected dose}}{BSA}} \quad (6)$$

where the same upper limit used for SUV_{water} was employed. These parameters were computed for each voxel of the tumor VOIs and the agreement of SUV_{water} with SUV_{fluci} RETENTION and SUV_{fluci} DELIVERY was assessed using Spearman's correlation coefficient.

Results

The activity of injected [¹⁸F]fluciclatide ranged between 290 and 383 MBq, and that of [¹⁵O]H₂O between 448 and 697 MBq. Due to tracer failure and patient comfort reasons, PET scans of both tracers were carried out in four patients; for two patients, only the [¹⁸F]fluciclatide data were obtained, and for the remaining patient, only the [¹⁵O]H₂O data were obtained.

Typical images of [¹⁵O]H₂O and [¹⁸F]fluciclatide are shown in Figure 1A,B, respectively. The quality of the fits was good for both tracers. Examples are displayed in Figure 2A for [¹⁵O]H₂O and Figure 2B for [¹⁸F]fluciclatide. In Table 2, the kinetic parameters for [¹⁵O]H₂O and the k_3/k_4 ratios of [¹⁸F]fluciclatide at the VOI level are reported. For completeness, we also reported SUV parameters for [¹⁸F]fluciclatide.

The k_3/k_4 ratio of [¹⁸F]fluciclatide was 5.39 ± 1.46 , in good agreement with our previous results in lung metastases ($k_3/k_4 = 6.09 \pm 3.04$). There was a good correlation (Pearson $r = 0.71$, p value = 0.06, Figure 3) between SUV_{fluci} RETENTION (x -axis) and k_3/k_4 (y -axis) at the VOI level supporting the use of the semi-quantitative parameter SUV_{fluci} RETENTION as a measure of retention.

To investigate the relationship between perfusion and [¹⁸F]fluciclatide retention, which was not feasible at the VOI level due to the low number of subjects completing both scans, we compared SUV_{water} with SUV_{fluci} RETENTION or SUV_{fluci} DELIVERY at the voxel level. As expected, SUV_{water} was well correlated with SUV_{fluci} DELIVERY, the correlation being statistically significant for voxels within all four tumors (p value $< 10^{-4}$ for all VOIs). The correlation between SUV_{water} and SUV_{fluci} RETENTION, on the other hand, was not statistically






Table 2 Kinetic parameters for $[^{15}\text{O}]\text{H}_2\text{O}$ and $[^{18}\text{F}]\text{fluciclatide}$ at the VOI level

Patient number	$K_1 [^{15}\text{O}]\text{H}_2\text{O}$ (mL/cm ³ /min)	$k_2 [^{15}\text{O}]\text{H}_2\text{O}$ (L/min)	$k_3/k_4 [^{18}\text{F}]\text{fluciclatide}$ (unitless)	SUVfluci DELIVERY (m ² /L)	SUVfluci RETENTION (m ² /L)
1	0.15	0.32	4.34	0.070	0.049
2	0.16	0.38	4.37	0.137	0.072
3	0.38	0.61	4.87	0.045	0.064
4	N/A	N/A	7.81	0.050	0.087
5	N/A	N/A	6.57	0.040	0.070
6	0.68	0.88	N/A	N/A	N/A
(Tumor#1)					
6	0.39	0.62	N/A	N/A	N/A
(Tumor#2)					
7	0.44	0.72	4.38	0.077	0.062

significant (Spearman p value >0.15 for all tumors). This information is displayed in Figure 4, which shows the relationship between SUVwater (x -axis) and SUVfluci DELIVERY (y -axis, Figure 4A,C,E,G for patients 1, 2, 3, and 7, respectively) and between SUVwater and SUVfluci RETENTION (y -axis, Figure 4B,D,F,H). The plots on the same row correspond to the same patients and the continuous line is the fitted line of equation $y = mx + q$. Whereas a monotonic relationship can be noticed between SUVwater and SUVfluci DELIVERY, there is no clear visual relationship between SUVwater and SUVfluci RETENTION.

Discussion

There is an increasing need for effective biomarkers which can reliably predict the response to novel therapeutics acting as angiogenesis inhibitors or as vascular disrupting






Figure 4 Relationship between fluciclatide delivery and water SUV (A,C,E,G) and between SUV fluciclatide retention and SUV for water (B,D,F,H). There was a lack of relationship between between SUV fluciclatide retention and SUV for water.

agents *in vivo*, and the RGD-based ligand, [^{18}F]fluciclatide, is very promising in this respect. Given the haemodynamic context of angiogenesis, the uptake characteristics of a good biomarker should be independent of blood flow. Consequently, the objective of this study, which is of scientific relevance to the use of this and possibly other RGD-based ligands, was to assess the dependency of [^{18}F]fluciclatide uptake on perfusion. The major finding of the study is that, at the voxel level, [^{18}F]fluciclatide retention is not correlated with perfusion measured by [^{15}O]H₂O uptake. We contrast this finding with a good agreement, as expected, between [^{15}O]H₂O uptake and [^{18}F]fluciclatide delivery suggesting that the lack of correlation between [^{15}O]H₂O uptake and [^{18}F]fluciclatide retention was not due to noise. Incidentally, the two-tissue compartment model which we validated for [^{18}F]fluciclatide in our previous report proved to be appropriate also for this dataset, and the mean k_3/k_4 ratio obtained in this study

(5.39 ± 1.46) was in good agreement with the results obtained in lung metastases ($k_3/k_4 = 6.09 \pm 3.04$).

The main limit in this initial study is the small sample size, as only four out of seven patients successfully completed both scans, which hampered the quantification of the relationship between K_1 of [^{15}O]H₂O and [^{18}F]fluciclatide k_3/k_4 at the VOI level. In this regard our future plan is to test further these preliminary findings on a larger cohort of subjects and also to apply/develop appropriate noise-reduction approaches which will allow us to compare K_1 maps of [^{15}O]H₂O and k_3/k_4 of [^{18}F]fluciclatide at the voxel level.

Conclusion

In conclusion, these preliminary results support the view that [^{18}F]fluciclatide binding (retention) is not dependent on perfusion, highlighting the potential of this radiotracer in the study of receptors expressed on the

neovasculature. The study supports the use of late imaging protocols (60 min post injection) for assessment of [^{18}F]fluciclatide uptake.

Abbreviations

BSA: Body surface area; HPLC: High-performance liquid chromatography; NSCLC: Non-small cell lung cancer; RGD: Arginine-glycine-aspartate; SUV: Standardised uptake value; VOI: Volume of interest; WNLSS: Weighted non-linear least squares; WRSS: Weighted residual sum of squares.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LK contributed to the study design, data acquisition and analysis, manuscript writing and review. GT contributed to the data analysis, manuscript writing and review. CB, JL, MG and SM contributed to the study design and manuscript review. FT and EO contributed to the study design, manuscript writing, and critical review. All authors read and approved the final manuscript.

Acknowledgements

This study was funded by the MRC (programme grant MC_A652_5PY80), Experimental Cancer Medicine Centre grant C37/A7283, and an NIHR clinician scientist fellowship grant (LKenny 09/009) and supported by the NIHR Cancer Clinical Research Network UK. We wish to thank Kasia Kozłowski and Laura Maher, the radiographers and staff of Imanet and GE Healthcare for their assistance with this project. This study was supported by NIHR Cancer Clinical Research Network.

Author details

¹Department of Surgery and Cancer, Hammersmith Campus, Imperial College London, London, UK. ²Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK. ³Centre for Neuroimaging, Institute of Psychiatry, King's College London, London, UK. ⁴Royal Marsden NHS Trust, London, UK.

Received: 8 April 2014 Accepted: 20 May 2014

Published: 8 August 2014

References

- Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of angiogenesis. *Nature* 2011, **473**:298–307.
- Daenen LG, Roodhart JM, Shaked Y, Voest EE: Vascular disrupting agents (VDAs) in anticancer therapy. *Curr Clin Pharmacol* 2010, **5**:178–185.
- Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F, Pandite L, Marreud S, De Brauwier A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). *J Clin Oncol* 2009, **27**:3126–3132.
- Weis SM, Cheresh DA: alphav Integrins in Angiogenesis and Cancer. *Cold Spring Harb Perspect Med* 2011, **1**:a006478.
- Avraamides CJ, Garmy-Susini B, Varner JA: Integrins in angiogenesis and lymphangiogenesis. *Nat Rev Cancer* 2008, **8**:604–617.
- Indrevoll B, Kindberg GM, Solbakken M, Bjurgert E, Johansen JH, Karlens H, Mendizabal M, Cuthbertson A: NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. *Bioorg Med Chem Lett* 2006, **16**:6190–6193.
- Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO: Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand [^{18}F]AH111585 in breast cancer patients. *J Nucl Med* 2008, **49**:879–886.
- Tomasi G, Kenny L, Mauri F, Turkeheimer F, Aboagye EO: Quantification of receptor-ligand binding with [^{18}F]fluciclatide in metastatic breast cancer patients. *Eur J Nucl Med Mol Imaging* 2011, **38**(12):2186–2197.
- Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M: [^{18}F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. *Bioconjug Chem* 2004, **15**:61–69.

- Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M: Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer [^{18}F]galacto-RGD in cancer patients. *J Nucl Med* 2005, **46**:1333–1341.
- Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M, Colevas AD, Grossman SA: Positron emission tomography using [^{18}F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. *Clin Cancer Res* 2006, **12**:3942–3949.
- Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittermer SM, *et al*: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. *J Clin Oncol* 2007, **25**:1651–1657.
- Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B: Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. *Int J Radiat Oncol Biol Phys* 2006, **65**:1536–1543.
- Tomasi G, Bertoldo A, Bishu S, Unterman A, Smith CB, Schmidt KC: Voxel-based estimation of kinetic model parameters of the L-[1- ^{11}C]leucine PET method for determination of regional rates of cerebral protein synthesis: validation and comparison with region-of-interest-based methods. *J Cereb Blood Flow Metab* 2009, **29**:1317–1331.
- Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ: Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. *Neuroimage* 1997, **6**:279–287.

doi:10.1186/s13550-014-0030-x

Cite this article as: Kenny *et al.*: Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [^{18}F]fluciclatide kinetics and [^{15}O]H₂O PET. *EJNMMI Research* 2014 **4**:30.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com